mRNA-Based Cancer Vaccine Shows Promise in Halting Cancer Return and Spread

Moderna and Merck have announced promising results from a late-stage clinical trial for their experimental mRNA-based cancer vaccine, intismeran, designed to prevent cancer recurrence and spread. The personalized vaccine, given in combination with Merck's immunotherapy Keytruda, demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival and reduced the spread of cancer in patients with high-risk melanoma. This marks the first time an mRNA-based cancer treatment has successfully cleared a Phase 3 trial.

The Phase 3 INTerpath-001 trial involved 1,137 patients with stage IIB to IV melanoma who had their tumors surgically removed. Patients received either the combination therapy of intismeran and Keytruda or Keytruda alone. Building on earlier Phase 2 results that showed a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis after five years, the current Phase 3 findings further solidify the vaccine's potential.

While full detailed data from the interim analysis are yet to be released, the companies indicated no new safety signals emerged during the trial. These positive outcomes pave the way for Moderna and Merck to present the data at an upcoming international medical meeting and engage with regulatory bodies for potential approval, which could be a landmark moment for personalized mRNA-based cancer therapies.